Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Extended Half-Life Clotting Factors Cut Infusions, Hike Prices

Publish date:: May 1, 2019

Key clinical point: Extended half-life clotting factors cut infusion frequency but cost much more.

Major finding: Extended half-life factor IX halved the number infusions, but increased the cost from $697,497 to more than $1 million in a year.

Study details: The study examined usage patterns in nearly 8,000 patients over 18 months.

Disclosures: The study was funded HTRS/ATHN Dataset Research Engagement and a DREAM Award from the Hemostasis and Thrombosis Research Society. Dr. Croteau reported consulting for Bayer, Bioverativ, Biomarin, CSL-Behring, and other companies.

Citation:

Croteau SE et al. Haemophilia. 2019. doi: 10.1111/hae.13758.

This Week's Must Reads

In UC patients, tofacitinib tied to modest, reversible lipid increases, infrequent cardiovascular events,

No clear-cut evidence of vedolizumab effect in retrospective study of primary sclerosing cholangitis,

Certolizumab may reduce uveitis flares, axSpA disease activity,

Bilateral mastectomy reduces second breast cancer risk, but not deaths,

Reward, decision-making brain regions altered in teens with obesity,

Must Reads in Hematology

Updated International Consensus Recommendations on Management of Acute Upper GI Bleeding,

Global Blood Supply Runs Low,

New Consensus Recommendations on Bleeding in Acquired Hemophilia,

Rivaroxaban trends toward higher thrombotic risk than vitamin K antagonists in APS,

Surveillance for hepatobiliary cancers in primary sclerosing cholangitis,